# Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer

> **NCT01875393** · PHASE3 · COMPLETED · sponsor: **Steba Biotech S.A.** · enrollment: 81 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** TOOKAD® Soluble

## Key facts

- **NCT ID:** NCT01875393
- **Lead sponsor:** Steba Biotech S.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-12
- **Final completion:** 2015-03
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2016-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01875393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01875393, "Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01875393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*